Biogen launches Flixabi (infliximab biosimilar) in the UK , a biosimilar version of Remicade.
Biogen has introduced its new biosimilar therapy Flixabi (infliximab biosimilar) in the UK for use in the treatment of a range of inflammatory conditions. The drug is a biosimilar version of Remicade, Johnson and Johnson's established immunology treatment, and is indicated for use in the treatment of Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
Flixabi was approved by the European Commission in May and has demonstrated in a 54-week, phase III clinical study that it offers comparable safety and equivalent efficacy to Remicade. According to Biogen, the conditions Flixabi is indicated for affect more than 600,000 people in the UK and can cost the NHS up to 470 million pounds every year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins